Artivion, Inc.
AORTHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeArtivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The $1.22B market capitalization puts AORT squarely in small-cap range for its industry. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system.
Market Cap
$1.22B
Beta
1.25
P/E (TTM)
104.42
P/E (Fwd)
34.81
EPS (TTM)
$0.24
EPS (Fwd)
$0.72
ROE
3.1%
ROA
2.8%
Cash
$55.8M
Total Debt
$258.2M
Free CF
-$7.3M
52W Change
-17.8%
Annual Financials
Cash vs Debt
Artivion, Inc. carries $258.2M in total debt against $55.8M in cash reserves — debt is roughly 4.6x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow is running at -$7.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of 3.1% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 2.8% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $313.8M (2022) to $441.3M (2025), reflecting a 41% increase over the period.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. At over 50x earnings, AORT carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Artivion, Inc. and its sector.